Appointments at Aphena, Acino and blue inspection body – People on the move

in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at Aphena, Acino and blue inspection body.

Thomas Bieringer has been appointed as managing director of INVITE GmbH, a manufacturing research joint venture between Bayer Technology Services and Technical University Dortmund. Bieringer has worked at Bayer since 1997.

Aphena Pharma Solutions has named Mary Foster as vice president (VP) of quality and regulatory affairs. Foster has worked in the sector for 25 years, most recently at Catalent Pharma Solutions.

Kip Martin has joined Columbia Laboratories (as VP, business development. Martin has served as a consultant to Columbia Laboratories in recent months while also supporting Inspirion Delivery Techonologies.

Blue inspection body Gmbh has hired Bohong Meng as co-auditor. Meng will be focused on assessing good manufacturing practices (GMP) of Asian active pharmaceutical ingredient (API) producers.

Christian Pangratz has been appointed as chief business officer at Activaero. Pangratz joins from Nektar Therapeutics to succeed Henrik Luessen who has left to focus on his consultancy business. Luessen will continue to support Activaero on a part time basis.

Acino has added Ulf-Hergen Westphal to group management. Westphal joined Acino as head group quality on March 1 2011 after holding similar positions at several pharmaceutical companies.

Jeffrey Walsh has joined bluebird bio as chief operating officer. Walsh has previously worked at Taligen Therapeutics, Inotek Pharmaceuticals, EXACT Sciences, PathoGenesis and SmithKline Beecham. Bluebird bio has also added Daniel Lynch to its board of directors.

Xanodyne Pharmaceuticals has named Fabrice Egros as chief operating officer. Egros has 20 years of pharmaceutical experience from working at UCB, Sanofi and Parke-Davis.

Allen Barnett has stepped down as CEO of Kinex Pharmaceuticals. Barnett was the founding CEO of Kinex and will be succeeded by Johnson Lau, who is currently executive chairman of the company. Lau has worked at Ribapharm, ICN Pharmaceuticals and Schering-Plough.